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Background: Myelolipoma is a rare neoplasm composed of yellowish adipose tissue and reddish-brown tissue
corresponding to hematopoietic or hemorrhages. It typically occurs in adrenal glands as a solitary, well-circumscribed
mass, and the thoracic location is extremely unusual.
Case presentation: We present a rare case who is a 54 years old male with bilateral Myelolipoma of the posterior
mediastinum. He underwent the surgery via video-assisted thoracic surgery both sides interval 3 months. Histological
examination showed both tumors consisted of mature fat tissue and hematopoietic tissue, including myeloid, erythroid,
and megakaryocytic elements surrounded. We discussed the etiology, histopathology, differential diagnosis and
recommended management of extra-adrenal myelolipoma and analyzed the features of the thoracic myelolipoma
including mediastinal and pulmonary location.
Conclusions: Literature review showed 16 similar cases, with a 2/1 male/female ratio and a mean age of 58 years.
Eight of sixteen cases were observed in the mediastinum and six of sixteen cases were displayed in the pulmonary
and one showed on the chest wall. CT and MRI scans are able to indicate the presence of extra-adrenal myelolipoma.
Pathological analysis is an effective method to clarify the diagnosis. Observation and surgery are two regular treatment
methods. Small, asymptomatic tumors should be monitored, while large tumors that cause unendurable symptoms
may be removed by surgery.
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Myelolipoma is encapsulated and composed of yellowish
adipose tissue and reddish-brown tissue corresponding
to hematopoietic or hemorrhages [1]. It was first re-
ported by Gierke in 1905 and its generally accepted
name, “myelolipoma” was purposed by Oberling in 1929
[2]. Most myelolipomas were confronted incidentally
during autopsy and their incidence was estimated to vary
from 0.01% to 0.2%. The most common site of involve-
ment is the adrenal gland. Extra-adrenal myelolipomas
may occur in the retroperitoneum, pelvis, presacral area,
stomach, liver and even in the thyroid glands; they are
seldom seen in the thorax [3]. Herein we report on a
rare case of a bilateral myelolipoma, extra-adrenal mye-
lolipoma (EAM) located in the posterior mediastinum.
And we also try to analyze the features of the thoracic
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A 54-year-old man was referred to our hospital for as-
sessment of two posterior mediastinal masses that was
detected on chest radiography during a routine health
check. He denied the following symptoms including the
presence of chest pain, hoarseness, hemoptysis, cough
and dyspnea. He was a non-smoker and had no expos-
ure to any environmental fumes or dust. Physical exam-
ination revealed normal breath sounds in both of the
lung fields. Laboratory findings were within normal
limits. In these examinations, hematology tests and bio-
chemistry tests were within regular levels. His Pulmonary
function tests and cardiovascular examination revealed
normal performance. Plain chest computed tomography
(CT) scans two paravertebral masses with well-defined
margins, well demarcated from the descending aorta in the
posterior mediastinum measuring 7.0 × 5.5 cm of the left
one and 3.8 × 2.8 cm of the right one in size. There was no
destruction of adjacent bone structures, no pleural effusion
or infiltration of surrounding tissues and no evidenced. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Contrast-enhanced CT scans showed obvious enhance-
ment in soft tissue masses (Figure 1A, 1B). Magnetic
resonance imaging (MRI) included axial scan, and multi-
planar reconstructions (MPRs) on the coronal and sagittal
planes (Figure 2A, 2B, 2C) revealed that both of the masses
extending from levels T9-10 in the coronal planes. Mixed-
signal lesions, mainly equal to a T1/T2 signal, were ob-
served. In the marginal regions, a cystic lesion exhibited
longer T1 and T2. There was no involvement of the verte-
bral canal and the bony structure was normal.
As diagnosis was not established through imaging, sur-
gery was scheduled. We approached the left tumor which
was removed by en bloc resection via video-assistedFigure 1 Chest X-ray and contrast-enhanced CT features of the
case. A: Posteroanterior chest X-ray showing a bilateral mass in the
posterior mediastinum. B: Contrast-enhanced CT scan showing a
bilateral thoracic paravertebral mass.thoracic surgery (VATS) rather than the thoracotomy.
There was no invasion into the adjacent structures. After
careful attention to hemostasis, a chest tube was placed to
drain the pleural cavity, and the left lung was reinflated
under direct vision. Three months later the right-sided le-
sion of 3.8 cm in diameter was also excised. Grossly, both
tumors disclosed a thin capsule of soft consistency and
reddish-brown color. Microscopically, both tumors con-
sisted of mature fat tissue and hematopoietic tissue,
including myeloid, erythroid, and megakaryocytic ele-
ments surrounded (Figure 3A, 3B, 3C). Based on these
findings, extra-adrenal myelolipoma was diagnosed. The
postoperative course was uneventful. The patient was
followed up for 5 months without evidence of recurrence
to date.
Conclusions
Myelolipoma is a relatively uncommon benign tumor,
composed of mature adipose tissue and hematopoietic
elements. Myelolipoma occurs at any age, which varied
from 12 to 93 years [2,4], however, patients with EAM
are generally older (mean age 64 years) than patients
with adrenal myelolipoma (mean age 55 years) [5]. The
male to female ratio ranged from 2:1 to 1:1 [5,6]. As in
our analysis, the male to female ratio was 2:1 and the
mean age was 58 years (Table 1).
The exact pathogenesis of myelolipoma is not clear at
present. Historically, there are 3 theories of the patho-
genesis of myelolipomas. The first is that myelolipomas
are derived from bone marrow emboli that lodge in the
adrenal gland or other sites. The second theory suggests
that myelolipomas are derived from embryonic primitive
mesenchymal cells. The third theory suggests that mye-
lolipomas arise from metaplastic transformation of ad-
renal (or other sites) stromal cells in response to stimuli.
As Dieckmann KP et al. [23] reported, the hypotheses of
the cause of EAM include degenerative changes in hy-
perplastic tumor cells, metaplasia in primary stem mes-
enchymal cells of the adrenal cortex, and displacement
of differentiated bone marrow cells during embryogen-
esis. Chen and colleagues suggested that in patients with
anemia, long-lasting erythropoietic stimulation may play
a role in the development of EAM [24]. Once in a while,
EAM may be accompanied by endocrine disorders like
Cushing’s syndrome, Addison’s disease, Cohn’s syndrome,
phaeochromocytoma, diabetes mellitus, or even obesity
and hypertension [25]. Therefore, some authors emphasize
that development of EAM may be correlated with pro-
longed excessive steroid production, or genome defects of
the endocrine glands responsible for multiple endocrine
neoplasia type 1 [24].
EAMs are typically asymptomatic. They tend to be in-
cidentally discovered during radiological investigation of
symptoms unrelated to myelolipoma. In our analysis, most
Figure 2 MRI features of the case. A: MRI scans reveals two masses in the posterior mediastinum. B: MPR on coronal plane shows a bilateral
thoracic paravertebral mass. C: MPR on sagittal plane confirms the left mass in the posterior mediastinum.
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some patients with mediastinum myelolipoma presented
with productive cough [9], the stiff neck [13], dull back
pain and a cough [14] or central chest pain [15]. The pa-
tients with pulmonary myelolipoma complain of fever [16],
productive cough [17,20] or intractable lumbago [19] and
the others were asymptomatic (Table 1). There was no pain
or cough in our case caused by the lesion, but it was de-
tected from the chest radiography during a routine health
check.Figure 3 Histological and immunoistochemical features. A: The freshly
hematopoietic elements admixed with adipose tissue (X100). C: High powe
hemotopoietic elements, including megakaryocytes and cells of regular graBecause these tumors are rare, criteria for diagnosing
EAM radiologically do not exist. Characteristics of mye-
lolipoma are deduced to apply to these structures which
present in a variety of locations [26]. Chest radiographs
are the most generally performed imaging study to
evaluate the mass, but it may not be possible to distin-
guish myelolipoma from others. Myelolipoma can be re-
liably diagnosed by either computed Tomography (CT)
or magnetic resonance imaging (MRI). Radiological im-
aging typically displays a well-circumscribed mass with aresected mass showing its circumscription. B: H&E staining reveals
r magnification (X400) shows very few adipocytes admixed with
nulopoietic and erythropoietic cell lineages.
Table 1 Clinicopathological features of the primary myelolipomas in thorax
Case Age (years) Sex Location Number Tumor size (cm) Treatment Follow up Author
1 68 M Right posterior mediastinum Single Not determined VATS Alive Ema T [7]
2 56 M Posterior mediastinum Single 25*15 Thoracotomy Alive Vaziri M [8]
3 65 F Bilateral of mediastinum Mutiple φ4.5/φ6.5 Thoracotomy Alive Franiel T [9]
4 55 M Posterior mediastinum Single φ4 VATS Alive Koizumi J [10]
5 53 F Pleura Single Not determined Thoracotomy Alive Spanta R [11]
6 50 M Bilateral of mediastinum Mutiple Not determined Thoracotomy Alive Krismann M [12]
7 71 F Right anterior mediasinum Single 6*5.5*5.5 Thoracotomy Dead Krag D [13]
8 68 F Bilateral of mediastinum Multiple 3.1*10/2.5*9 Thoracotomy Alive Geng C [14]
9 46 M Right anterior mediastinum Single φ4.5 Thoracotomy Alive Mohan K [15]
10 57 F Right low lobe Single 13*10*2.5 VATS Alive Huang W [16]
11 53 M Left upper lobe Single 2.3*1.2*1.0 Thoracotomy Alive Huang WT [17]
12 63 M Chest wall Single 2.0*1.5*1.2 VATS Alive Sagan D [18]
13 70 M Left low lobe Single 2 Chemotherapy Dead Sato K [19]
14 45 M Left upper lobe Single φ1.5 Thoracotomy Alive Lu X [20]
15 54 M Pulmonary Single Not determined Thoracotomy Alive Sabate CJ [21]
16 52 M Pulmonary Single Not determined Thoracotomy Dead Zunarelli E [22]
Shen et al. BMC Surgery 2014, 14:42 Page 4 of 6
http://www.biomedcentral.com/1471-2482/14/42heterogeneous appearance due to the varying propor-
tions of fat within the mass. Adipose tissue is character-
ized by low attenuation on CT imaging (i.e., −25 to −100
Hounsfield units). On MRI, fat displays high signal inten-
sity on T1-weighted images whereas the myeloid compo-
nent of these tumors has a T2-weighted signal. Contrast
enhancement with CT scan or MRI will vary depending on
the composition of the mass. Soft tissue components en-
hance whereas adipose tissue does not [27]. There is also a
word of caution in our case that patients with myelolipoma
are not only examined with axial scan but also checked
with MPRs on coronal plane and sagittal plane, because
they can be useful in preoperative diagnosis.
There is no agreement on how to manage EAM.
Daneshmand et al. [28] suggested that small asymptomatic
tumors (<4 cm in size) should be monitored, while symp-
tomatic tumors or large myelolipomas (>7 cm in size)
should be removed. Considering the potential progressive
enlargement of the lesion and the uncertain preoperative
diagnosis, most myelolipomas are surgically removed,
which is a useful method for treating myelolipomas and
the tumors generally do not recur, and in recent years this
operation has frequently been performed by using Video
Assisted Thoracic Surgery (VATS). In our table, only four
patients were operated by Video Assisted Thoracic Surgery
VATS and the others were treated with thoracotomy. Ac-
cording to the report of Sato K [19], the 70-year-old patient
presented with intractable lumbago and MRI detected
multiple bone tumours. CT of the chest indicated a large
mass in the right lower lobe and a small solitary nodule
with rim-like calcification in the left low lobe of the lung.Sputum cytology showed carcinoma cells. He was clinically
diagnosed as having lung cancer with multiple bone metas-
tases. Chemotherapy and radiation therapy had no effect,
and the patient died of respiratory failure. An autopsy was
performed after death and the small solitary nodule was di-
agnosed as myelolipoma. In the present case, the male
whose CT and MRI scans revealed two posterior medias-
tinal masses was operated by VATS. A roundish, para-
vertebral, encapsulated solid mass of soft consistency
measuring 7.0 cm in diameter was removed. Three months
later the right-sided lesion of 3.8 cm in diameter was also
excised.
Grossly, EAM is a solitary circumscribed mass ranging
in size from a few centimeters to 27 cm [29]. From our
table, the size of the masses ranged from 1 cm to 25 cm.
The tumor is usually spherical to ovoid, well circum-
scribed, sometimes surrounded by a pseudocapsule. The
cut surface typically has a variegated appearance, with
areas of greasy-appearing soft yellow tissue alternating
with irregular areas of dark red-brown friable tissue.
Microscopically, the tumor is composed of a variable ad-
mixture of mature adipose tissue with islands and nests
of hematopoietic elements of different percentages. The
cellularity of hematopoietic precursors is variable and
the three hematopoietic cell lineages (granulopoietic,
erythropoietic and megakaryocytic) are present. In some
cases, areas of infarction, hemorrhage, and rarely foci of
calcification are noted [30]. Bony spicules were rarely
noted and were only found in large tumors [18].
When the diagnosis of myelolipoma is considered, it
should be differentiated from other tumors. Pulmonary
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dullary hematopoiesis and hamartoma. Extramedullary
hematopoiesis usually occurs as a manifestation of myelo-
proliferative diseases or is a compensatory phenomenon
in various chronic anemias. In contrast to myelolipoma,
extramedullary hematopoiesis of the lung frequently
presents with multiple occurrences and ill-defined lesions.
Microscopically, extramedullary hematopoiesis is com-
posed predominantly of hematopoietic cells and erythroid
hyperplasia. Lung hamartomas generally consist of cartil-
age, fat, and connective tissue [31]. When myelolipoma is
composed predominantly of fat tissue, it is difficult to dis-
tinguish it from Liposarcoma. Macroscopically, a liposar-
coma consists usually of a large, well-circumscribed,
lobulated mass. Color varies from yellow to white de-
pending on the proportion of adipocytic, fibrous and/or
myxoid areas. Differential diagnosis of subpleural chest
wall masses should include lesions of similar clinical ap-
pearance, such as lipomas, lymph node metastases, and
in particular, neurogenic neoplasms. Posterior mediastinal
EAM must be considered in preoperative differential diag-
nosis, to differentiate it, not only from extramedullary
hematopoietic tumors but also from other tumors occur-
ring at these sites such as lymph node metastases, lymph-
omas or neurogenic tumors.
The usual natural history of EAM is benign although
they may enlarge and bleed. Some reports have shown
stable lesions with follow up from 3 to 62 months [18].
Small asymptomatic lesions may be managed expect-
antly. Radiological follow up is recommended due to the
potential for growth and hemorrhage. As in ours, surgi-
cal intervention is warranted to the patients who have
an unclear diagnosis or possess an enlarging tumor
mass. Long-term prognosis is excellent.
Although primary extra-adrenal myelolipoma is rare,
understanding its diagnosis and treatment are important.
If a patient is suspected to have primary extra-adrenal
myelolipoma by CT or MRI scans, this may be clarified
it by pathological analysis. Subsequently, the tumor may
be modified or removed by surgery, according to its ef-
fects on the body.
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